Acute Coronary Syndrome Clinical Trial
— SAMPAOfficial title:
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis After Loading Dose of Clopidogrel
Verified date | May 2017 |
Source | Federal University of São Paulo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction:
Platelet aggregation plays an important role in ischemic complications in patients
undergoing to percutaneous coronary intervention (PCI). The addition of clopidogrel, as a
second antiplatelet agent, to acetylsalicylic acid (ASA) was effective in reducing major
cardiovascular events in patients with acute coronary syndrome (ACS).
However, approximately 30% of ACS patients are resistant to clopidogrel, representing a
population of medically vulnerable and high risk for major cardiovascular events, including
myocardial infarction (MI), stent thrombosis and death.
In the randomized trial TRITON, prasugrel compared to clopidogrel was more effective in
significantly reducing the rates of MI (7.4% vs. 9.4%) and stent thrombosis (2.4% vs .1,1%)
in patients with ACS, however, patients treated with prasugrel showed higher rates of
bleeding (2.4 vs. 1.8%) and no difference in mortality. Upon analysis of subgroups is not
recommended its use in patients with a history of stroke in those older than 75 years and
weighing less than 60 kg.
The latest class of inhibitors of the P2Y12 receptor is the cyclopentyl-triazolopyrimidines
represented by ticagrelor. Unlike the thienopyridines, ticagrelor interacts with the
platelet receptors in a reversible way and has a beginning and peak of action faster.
The efficacy and safety of ticagrelor were evaluated in the study PLATO, where 18.624
patients with ACS were randomized to receive clopidogrel (75mg/day, with a loading dose of
300 to 600mg) or ticagrelor (90mg 2x/day with a loading dose of 180mg) The primary combined
endpoint (mortality from vascular causes, MI or stroke) at 12 months was significantly lower
in the ticagrelor (9.8% vs. 11.7%). There was no significant difference in the rates of
major bleeding in both groups. Moreover, the isolated analysis of the rates of MI, vascular
mortality and mortality from all causes showed statistically significant reduction in the
ticagrelor users. In this study, the main adverse effects were dyspnea and bradycardia.
The assessment of platelet reactivity may allow the individualization of antiplatelet
therapy. However, simply increasing the dose of clopidogrel in patients who persisted with
high platelet reactivity was not able to reduce the combined endpoint of cardiovascular
death, nonfatal myocardial infarction and stent thrombosis in six months.
In a population of patients with stable coronary artery disease, the substitution of
clopidogrel for ticagrelor showed a rapid and persistent decrease in platelet aggregation
measured by different laboratory methods. However, in patients with ACS subjected to PCI,
the assessment of platelet aggregation after the replacement of clopidogrel for prasugrel or
ticagrelor still requires evidence.
Objectives:
To evaluate the platelet response to ticagrelor and prasugrel in ACS patients with
ST-segment elevation submitted to thrombolysis.
To evaluate security in follow up of 30 days.
Methods:
The study will be a prospective, randomized, single-center (São Paulo Hospital - Federal
University of São Paulo), single-blind. The investigators will select 50 patients admitted
with ACS with ST-segment elevation submitted to thrombolysis and who underwent cardiac
catheterization between 3 to 24 hours in the case of reperfusion or immediately for rescue
angioplasty. Blood sample for analysis of platelet aggregation through the system VerifyNow
®, shall be obtained immediately after the procedure on patients on clopidogrel for at least
seven days in maintenance dose of 75mg or after 8 to 6 hours after the dose of 300mg and
600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the
dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of
60mg and maintained for thirty days at a daily dose of 10mg. A new blood sample and analysis
of platelet aggregation will be repeated after 2, 6 and 24 hours. The demographic and
clinical data of this population will be collected in specific form and stored in databases
for later analysis
Status | Completed |
Enrollment | 50 |
Est. completion date | October 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 75 Years |
Eligibility |
Inclusion Criteria: - less than 75 years - sign the consent form - Acute coronary syndrome with ST-segment elevation submitted to thrombolysis Exclusion Criteria: - use of IIbIIIa inhibitor - less than 60 kg - history of stroke - Patients with sick sinus syndrome, atrioventricular block second or third degree, not protected by pacemaker - Chronic obstructive pulmonary disease - Asthma - Heart failure class III / IV - renal replacement therapy - Use of inducers (carbamazepine, phenytoin, phenobarbital, rifampicin and dexamethasone) or inhibitors (ketoconazole, itraconazole, ritonavir, saquinavir, clarithromycin) potent enzyme PYP3A |
Country | Name | City | State |
---|---|---|---|
Brazil | Federal University of São Paulo | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Federal University of São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of change in platelet aggregation | time 0, 2, 6 and 24 hours | ||
Secondary | The number of incidence of bleeding | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|